Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent μ-opioid receptor agonists. (15th December 2022)
- Record Type:
- Journal Article
- Title:
- Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent μ-opioid receptor agonists. (15th December 2022)
- Main Title:
- Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent μ-opioid receptor agonists
- Authors:
- De Luca, Maria Antonietta
Tocco, Graziella
Mostallino, Rafaela
Laus, Antonio
Caria, Francesca
Musa, Aurora
Pintori, Nicholas
Ucha, Marcos
Poza, Celia
Ambrosio, Emilio
Di Chiara, Gaetano
Castelli, M. Paola - Abstract:
- Abstract: Recent trends of opioid abuse and related fatalities have highlighted the critical role of Novel Synthetic Opioids (NSOs). We studied the μ-opioid-like properties of isotonitazene (ITZ), metonitazene (MTZ), and piperidylthiambutene (PTB) using different approaches. In vitro studies showed that ITZ and MTZ displayed a higher potency in both rat membrane homogenates (EC50 :0.99 and 19.1 nM, respectively) and CHO-MOR (EC50 :0.71 and 10.0 nM, respectively) than [D-Ala 2, NMe-Phe 4, Gly-ol 5 ]-enkephalin (DAMGO), with no difference in maximal efficacy (Emax) between DAMGO and NSOs. ITZ also has higher affinity (Ki:0.06 and 0.05 nM) at the MOR than DAMGO in both systems, whilst MTZ has higher affinity in CHO-MOR (Ki=0.23 nM) and similar affinity in rat cerebral cortex (Ki = 0.22 nM). PTB showed lower affinity and potency than DAMGO. In vivo, ITZ displayed higher analgesic potency than fentanyl and morphine (ED50 :0.00156, 0.00578, 2.35 mg/kg iv, respectively); ITZ (0.01 mg/kg iv) and MTZ (0.03 mg/kg iv) reduced behavioral activity and increased dialysate dopamine (DA) in the NAc shell (max. about 200% and 170% over basal value, respectively. Notably, ITZ elicited an increase in DA comparable to that of higher dose of morphine (1 mg/kg iv), but higher than the same dose of fentanyl (0.01 mg/kg iv). In silico, induced fit docking (IFD) and metadynamic simulations (MTD) showed that binding modes and structural changes at the receptor, ligand stability, and the overallAbstract: Recent trends of opioid abuse and related fatalities have highlighted the critical role of Novel Synthetic Opioids (NSOs). We studied the μ-opioid-like properties of isotonitazene (ITZ), metonitazene (MTZ), and piperidylthiambutene (PTB) using different approaches. In vitro studies showed that ITZ and MTZ displayed a higher potency in both rat membrane homogenates (EC50 :0.99 and 19.1 nM, respectively) and CHO-MOR (EC50 :0.71 and 10.0 nM, respectively) than [D-Ala 2, NMe-Phe 4, Gly-ol 5 ]-enkephalin (DAMGO), with no difference in maximal efficacy (Emax) between DAMGO and NSOs. ITZ also has higher affinity (Ki:0.06 and 0.05 nM) at the MOR than DAMGO in both systems, whilst MTZ has higher affinity in CHO-MOR (Ki=0.23 nM) and similar affinity in rat cerebral cortex (Ki = 0.22 nM). PTB showed lower affinity and potency than DAMGO. In vivo, ITZ displayed higher analgesic potency than fentanyl and morphine (ED50 :0.00156, 0.00578, 2.35 mg/kg iv, respectively); ITZ (0.01 mg/kg iv) and MTZ (0.03 mg/kg iv) reduced behavioral activity and increased dialysate dopamine (DA) in the NAc shell (max. about 200% and 170% over basal value, respectively. Notably, ITZ elicited an increase in DA comparable to that of higher dose of morphine (1 mg/kg iv), but higher than the same dose of fentanyl (0.01 mg/kg iv). In silico, induced fit docking (IFD) and metadynamic simulations (MTD) showed that binding modes and structural changes at the receptor, ligand stability, and the overall energy score of NSOs were consistent with the results of the biological assays. Highlights: ITZ, MTZ showed high potency and affinity at MOR in native and recombinant system. ITZ reduced nociception and behavioral activity when compared to morphine or fentanyl. ITZ and MTZ stimulate in vivo DA transmission in the NAc shell. ITZ and MTZ displayed in silico properties consistent with the biological assays. … (more)
- Is Part Of:
- Neuropharmacology. Volume 221(2022)
- Journal:
- Neuropharmacology
- Issue:
- Volume 221(2022)
- Issue Display:
- Volume 221, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 221
- Issue:
- 2022
- Issue Sort Value:
- 2022-0221-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-12-15
- Subjects:
- GTPγS binding -- MOR binding -- In silico studies -- Dopamine -- Nitazenes -- Nociception -- Microdialysis
Neuropsychopharmacology -- Periodicals
Autonomic Agents -- Periodicals
Neuropsychopharmacologie -- Périodiques
Neuropsychopharmacology
Periodicals
Electronic journals
615.78 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00283908 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.neuropharm.2022.109263 ↗
- Languages:
- English
- ISSNs:
- 0028-3908
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.517500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24140.xml